{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:55:22Z","timestamp":1779234922645,"version":"3.51.4"},"reference-count":18,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10,11]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Cytoreduction with obinutuzumab and ibrutinib followed by the addition of venetoclax has acceptable safety with no tumor lysis syndrome. This combination has preliminary activity including complete remissions with undetectable residual disease in relapsed or refractory CLL.<\/jats:p>","DOI":"10.1182\/blood-2018-05-853564","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T16:25:36Z","timestamp":1539275136000},"page":"1568-1572","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":95,"title":["Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia"],"prefix":"10.1182","volume":"132","author":[{"given":"Kerry A.","family":"Rogers","sequence":"first","affiliation":[{"name":"Division of Hematology,"},{"name":"The Ohio State University Comprehensive Cancer Center,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy S.","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyla A.","family":"Heerema","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Lozanski","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kami J.","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mollie E.","family":"Moran","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Reid","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Lucas","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"Division of Hematology,"},{"name":"The Ohio State University Comprehensive Cancer Center,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Thomas","family":"Whitlow","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of Hematology,"},{"name":"The Ohio State University Comprehensive Cancer Center,"},{"name":"Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2019111912400823200_B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111912400823200_B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111912400823200_B3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2019111912400823200_B4","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111912400823200_B5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"2019111912400823200_B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111912400823200_B7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"16","key":"2019111912400823200_B8","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9747","key":"2019111912400823200_B9","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"2019111912400823200_B10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"issue":"22","key":"2019111912400823200_B11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V128.22.1259.1259","article-title":"Inhibitors of Bruton\u2019s tyrosine kinase reduce anti-red blood cell response in a murine model of autoimmune hemolytic anemia","volume":"128","author":"Rogers","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2019111912400823200_B12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111912400823200_B13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/19420862.2015.989020","article-title":"Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies","volume":"7","author":"Duong","year":"2015","journal-title":"MAbs"},{"issue":"12","key":"2019111912400823200_B14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111912400823200_B15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"2019111912400823200_B16","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111912400823200_B17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2019111912400823200_B18","first-page":"431","article-title":"Initial results of the phase 2 treatment naive cohort in a phase 1b\/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia","volume":"130","author":"Rogers","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/15\/1568\/1406690\/blood853564.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/15\/1568\/1406690\/blood853564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:27:10Z","timestamp":1574191630000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/15\/1568\/39320\/Phase-1b-study-of-obinutuzumab-ibrutinib-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,10,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-05-853564","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}